• UPDATE : 2019.10.16 수 16:44
상단여백
기사 (전체 76건)
South Korea’s National Soccer Team Prepared 2018 Russia World Cup with Vaccination
Sanofi Pasteur in Korea(General Manager: Baptiste de Clarens) announced tha...
라인
Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries
Family-owned pharmaceutical company Boehringer Ingelheim today presented it...
라인
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company fo...
라인
Three Leading Animal Health Companies Join Hands to Launch World-Class Vaccine Joint Venture Targeting Foot-and-Mouth Disease in China
Shaanxi Meili Omni-Honesty Animal Health Co., Ltd., China’s world-class vac...
라인
Boehringer Ingelheim Starts New Campaign: 'Why wait in IPF?'
On Rare Disease Day, 28 February, Boehringer Ingelheim emphasises the quest...
라인
Takeda Announces Its Certification in Select Group of Global Top Employers 2018
Takeda Pharmaceutical Company Limited (TOKYO: 4502), (“Takeda”) today annou...
라인
Takeda’s Zika Vaccine Candidate Receives U.S. FDA Fast Track Designation
Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announc...
라인
European Commission Approves ADCETRIS(brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy- Providing an Innovative Treatment Option to Patients
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the ...
라인
Takeda Recognized as a Global 100 Most Sustainable Corporation for Third Consecutive Year
Takeda Pharmaceutical Company Limited [TOKYO:4502], (“Takeda”) is proud to ...
라인
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS in Frontline Advanced Hodgkin Lymphoma
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc....
라인
AstraZeneca’s Calquence Shows Potential in Chronic Lymphocytic Leukaemia Trials
AstraZeneca and Acerta Pharma, its haematology research and development cen...
라인
Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M€
Boehringer Ingelheim announced an increase in funding for its corporate ven...
라인
AstraZeneca and Chi-Med’s Savolitinib Shows Encouraging Clinical Activity in 2nd-Line EGFR Mutation-positive Lung Cancer with MET-amplification
AstraZeneca and its partner Chi-Med today presented preliminary safety and ...
라인
Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017
2017 marks a year of significant advancement for Boehringer Ingelheim as it...
라인
AstraZeneca’s Calquence Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial
AstraZeneca and Acerta Pharma, its haematology research and development cen...
라인
Takeda Initiates Phase 1 Clinical Trial of Zika Vaccine Candidate
(Business Wire/Korea Newswire) Takeda Pharmaceutical Company Limited [TSE: ...
라인
Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to the Scientific Community Via opnMe.com To Unlock Their Full Potential
(Business Wire/Korea Newswire) Boehringer Ingelheim today announced the lau...
라인
Takeda Receives Positive CHMP Opinion for ADCETRIS for CD30-Positive Cutaneous T-Cell Lymphoma
(Business Wire/Korea Newswire) Takeda Pharmaceutical Company Limited (TSE: ...
라인
Key sub-analyses of RE-DUAL PCI showed large reductions in the incidence of bleeding complications if Pradaxa dual therapy was used instead of warfarin triple therapy
(Business Wire/Korea Newswire) Boehringer Ingelheim has shared sub-analyses...
라인
New RE-VERSE AD analyses provide additional insights on impact of Praxbind in Pradax patients with gastrointestinal bleeding or needing emergency surgery
(Business Wire/Korea Newswire) Boehringer Ingelheim announced results from ...
Back to Top